NEOG Neogen Corp
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC EDGAR official
Market Value*
$972.14M
Revenue (FY)
$870.40M 2026-05-31
Net Income (FY)
$-7.90M
second period of the Cenozoic Era.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC EDGAR official
second period of the Cenozoic Era.